-
Mashup Score: 0Do Liver Conditions Up Risk of Severe COVID-19? It Depends - 3 year(s) ago
No higher risk of death in liver transplant, but more severe disease in patients with cirrhosis, NAFLD
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3Surveillance Models Score Liver Ca Risk After HCV Cure - 3 year(s) ago
Studies refute idea HCV cure is equal to elimination of HCC risk, expert says
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2Liver Fibrosis Assessment Advocated for Routine T2D Care - 3 year(s) ago
Pilot study ID’d ‘significant’ number of patients with advanced liver disease despite normalenzymes
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2
Significant reductions versus liraglutide, placebo, but GI effects questioned
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Cirrhosis Patients OK for Fecal Transplant - 4 year(s) ago
Safe and possibly effective for alcohol cravings
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Early Studies Make Headway in Chronic HBV Tx - 4 year(s) ago
Investigational agents prove safe, tolerable
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Combo Tx Upped Transplant-Free Survival in Japanese PBC Patients - 4 year(s) ago
Adding bezafibrate to UDCA showed promise in large retrospective analysis
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
New data showing efficacy and tolerability with ADP-A2AFP, alpha-fetoprotein–directed specific peptide enhanced affinity receptor T-cells, suggest that further research evaluating the 5 billion or more cell dosing regimen is warranted in hepatocellular carcinoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
New data showing efficacy and tolerability with ADP-A2AFP, alpha-fetoprotein–directed specific peptide enhanced affinity receptor T-cells, suggest that further research evaluating the 5 billion or more cell dosing regimen is warranted in hepatocellular carcinoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0First-in-Human T-Cell Therapy Warrants Further Investigation With Acceptable Tolerability and Efficacy Signals - 4 year(s) ago
New data showing efficacy and tolerability with ADP-A2AFP, alpha-fetoprotein–directed specific peptide enhanced affinity receptor T-cells, suggest that further research evaluating the 5 billion or more cell dosing regimen is warranted in hepatocellular carcinoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
ICYMI: "This is very important data, because there was a lot of concern with transplant patients that there may be a higher risk of dying." @AmerGastroAssn #ILC2020 #AGAConfRep https://t.co/7vqG4GELJC https://t.co/Zvb8IodOLj